Cytek Biosciences, Inc.
CTKB
$5.76
$0.132.31%
| Weiss Ratings | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D | |||
| Rating Factors | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.31 | |||
| Price History | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.68% | |||
| 30-Day Total Return | -12.61% | |||
| 60-Day Total Return | -21.06% | |||
| 90-Day Total Return | -34.36% | |||
| Year to Date Total Return | -32.81% | |||
| 1-Year Total Return | -45.07% | |||
| 2-Year Total Return | -35.57% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -54.26% | |||
| 52-Week Low % Change | 48.16% | |||
| Price | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $12.31 | |||
| 52-Week Low Price | $3.80 | |||
| 52-Week Low Price (Date) | Nov 08, 2023 | |||
| 52-Week High Price (Date) | May 04, 2023 | |||
| Valuation | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 774.48M | |||
| Enterprise Value | 526.20M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.09 | |||
| Earnings Per Share Growth | -978.85% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.10 | |||
| Price/Book (Q) | 1.97 | |||
| Enterprise Value/Revenue (TTM) | 2.53 | |||
| Price | $5.96 | |||
| Enterprise Value/EBITDA (TTM) | -24.05 | |||
| Enterprise Value/EBIT | -18.53 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 133.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 877 922 9835 | |||
| Address | 47215 Lakeview Boulevard Fremont, CA 94538 | |||
| Website | cytekbio.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -13.64% | |||
| Profit Margin | -6.29% | |||
| Management Effectiveness | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.25% | |||
| Return on Equity | -- | |||
| Income Statement | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 193.01M | |||
| Total Revenue (TTM) | 193.01M | |||
| Revenue Per Share | $1.45 | |||
| Gross Profit (TTM) | 109.43M | |||
| EBITDA (TTM) | -20.30M | |||
| EBIT (TTM) | -26.35M | |||
| Net Income (TTM) | -12.15M | |||
| Net Income Avl. to Common (TTM) | -12.15M | |||
| Total Revenue Growth (Q YOY) | 20.48% | |||
| Earnings Growth (Q YOY) | 48.01% | |||
| EPS Diluted (TTM) | -0.09 | |||
| EPS Diluted Growth (Q YOY) | 65.73% | |||
| Balance Sheet | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 262.41M | |||
| Cash Per Share (Q) | $1.96 | |||
| Total Current Assets (Q) | 392.06M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 393.06M | |||
| Current Ratio (Q) | 6.973 | |||
| Book Value Per Share (Q) | $3.01 | |||
| Total Assets (Q) | 494.46M | |||
| Total Current Liabilities (Q) | 56.23M | |||
| Total Debt (Q) | 14.14M | |||
| Total Liabilities (Q) | 101.39M | |||
| Total Common Equity (Q) | 393.06M | |||
| Cash Flow | CTKB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -93.89M | |||
| Cash from Financing (TTM) | -41.81M | |||
| Net Change in Cash (TTM) | -131.87M | |||
| Levered Free Cash Flow (TTM) | -400.70K | |||
| Cash from Operations (TTM) | 5.28M | |||
